| 摘要: |
| 目的:探讨不同剂量布地奈德长期雾化吸入对小儿哮喘的临床效果。方法:选取2016 年我院儿科收治的哮喘急性发作患儿100 例,采用随机数表法分为高剂量组和低剂量组各50 例,在常规治疗基础上,分别给予每次1.0 mg 和每次0.5 mg 的布地奈德雾化吸入,每隔8 h 一次,连续治疗7 d;急性期后,分别以400 µg/ d 和200 µg/ d 的小剂量布地奈德混悬液雾化吸入维持治疗3 个月,症状控制后剂量减半,总疗程1 年。另选同期来我院免疫接种的健康儿童30 例作为对照组。比较两组患儿的总有效率、症状改善情况及不良反应,及治疗前、治疗3 个月、12 个月时的血清IL-4、IL-5、TNF-α、VEGF、IgE 水平。结果:高剂量组治疗总有效率96.00%,高于低剂量组的82.00%(P<0.05)。高剂量组患儿的喘息、咳嗽、哮鸣音、呼吸困难缓解时间及住院时间均短于低剂量组(P 均<0.01)。治疗前两组患儿的IL-4、IL-5、TNF-α、VEGF、IgE 水平均高于对照组(P 均<0.05);治疗后两组患儿各指标水平均逐步下降,且治疗3 个月时高剂量组均低于低剂量组(P 均<0.05)。两组患儿治疗期间均无明显不良反应发生。结论:高剂量布地奈德雾化吸入能更有效地缓解哮喘患儿的症状,降低气道高反应性,无明显不良反应,值得临床推广应用。 |
| 关键词: 儿童 哮喘 布地奈德 雾化吸入 高剂量 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2019.03.011 |
|
| 基金项目: |
|
| Long-Term Aerosol Inhalation of Different Doses of Budesonide in the Treatment of Children with Asthma |
| Shen Fangfang, Zhang Lili, Yang Xiumei, Wang Jia, Xiao Yingying, Zhang Shuxin, Li Shuyu |
| (Hebei Shexian Hospital, Hebei Handan 056400, China) |
| Abstract: |
| Objective: To investigate the clinical effects of long-term aerosol inhalation of different doses of budesonide in the treatment
of children with asthma. Methods: Totally 100 children with acute asthma attack admitted into our hospital in 2016 were extracted to be divided into the high-dose group and the low-dose group, with 50 cases in each group. On the basis of the conventional treatment,
budesonide erosol inhalation of 1.0 mg/ time and 0.5 mg/ time was given, once every 8 h for 7 d. After the acute phase, low doses of
budesonide suspension were aerosolized and inhaled for 3 months at 400 µg/ d and 200 µg/ d, and the dose was halved after the symptom
control, the total treatment course was 1 year. Another 30 healthy children who were vaccinated in our hospital during the same period were selected as the control group. The total effective rate, symptom improvement, adverse drug reactions, the levels of IL-4, IL-5,TNF-α, VEGF and IgE before treatment and after treatment of 3 and 12 months were compared. Results: The total effective rate of the high-dose group was 96.00%, higher than that of the low-dose group 82.00% (P<0.05). The remission time of gasping, coughing,
wheezing and dyspnea, length of stay of high-dose group were markedly shorter than those of the low-dose group (P <0.01). Before
treatment, the levels of IL-4, IL-5, TNF-α, VEGF and IgE in two groups were higher than those in the control group (P<0.05), but the
difference was not statistically significant (P>0.05). After treatment, the levels of all indicators in two groups were in a decreasing trend,and after treatment of 3 months, the high-dose group was lower than the low-dose group (P<0.05). There were no significant adverse drug reactions in both groups. Conclusion: Aerosol inhalation of high-dose budesonide can more effectively alleviate the symptoms of asthmatic children, reduce the airway hyperresponsiveness, without any obvious adverse drug reactions, and it is worthy of clinical application. |
| Key words: children asthma budesonide aerosol inhalation high-dose |
